================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13G
(RULE 13D-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULE 13D-1(B), (C) AND (D) AND AMENDMENTS THERETO FILED PURSUANT TO
RULE 13D-2
(AMENDMENT NO. )*
ARTES MEDICAL, INC.
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
04301Q100
(CUSIP Number)
JOHN R. COSTANTINO
NGN CAPITAL LLC
369 LEXINGTON AVE., 17TH FLOOR
NEW YORK, NY 10017 (212) 972-0077
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
NOVEMBER 28, 2007
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[_] Rule 13d-1(b)
[_] Rule 13d-1(c)
[X] Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
================================================================================
Page 1 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 2 OF 9 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
NGN Biomed Opportunity I, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 0
SHARES
--------------------------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 625,920
EACH REPORTING
--------------------------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
625,920
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
625,920
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES [_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.77%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
Page 2 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 3 OF 9 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
NGN BioMed I, GP, L.P.
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 0
SHARES
--------------------------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 625,920
EACH REPORTING
--------------------------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
625,920
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
625,920
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES [_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
3.77%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
Page 3 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 4 OF 9 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Germany
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 0
SHARES
--------------------------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 425,508
EACH REPORTING
--------------------------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
425,508
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
425,508
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES [_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.73%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
PN
--------------------------------------------------------------------------------
Page 4 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 5 OF 9 PAGES
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
1 NAMES OF REPORTING PERSONS.
NGN Capital, LLC
--------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) [_]
(b) [_]
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
--------------------------------------------------------------------------------
5 SOLE VOTING POWER
NUMBER OF 0
SHARES
--------------------------------------------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 1,164,474
EACH REPORTING
--------------------------------------------------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 0
--------------------------------------------------------------------------------
8 SHARED DISPOSITIVE POWER
1,164,474
--------------------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,164,474
--------------------------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES [_]
--------------------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
6.69%
--------------------------------------------------------------------------------
12 TYPE OF REPORTING PERSON
OO
--------------------------------------------------------------------------------
Page 5 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 6 OF 9 PAGES
--------------------------------------------------------------------------------
ITEM 1 (a) Name of Issuer: Artes Medical, Inc.
(b) Address of Issuer's Principal Executive Offices:
5870 Pacific Center Boulevard
San Diego, California
ITEM 2 (a) Names of Persons Filing:
This Statement is being filed by (1) NGN Biomed Opportunity I, L.P.
("NGN Biomed Opportunity I"); (2) NGN BioMed I, GP, L.P. ("NGN GP")
which is the sole general partner of NGN Biomed Opportunity I; (3)
NGN Biomed Opportunity I GmbH & Co. Beteiligungs KG ("NGN Biomed
Opportunity I GmbH"); and (4) NGN Capital, LLC ("NGN Capital"),
which is the sole general partner of NGN GP and the managing
limited partner of NGN Biomed Opportunity I GmbH (each a "Reporting
Person" and collectively, the "Reporting Persons").
(b) Address of Principal Business Office or, if none, Residence:
The principal business address of each of the Reporting Persons is
369 Lexington Avenue, 17th Floor, New York, New York 10017.
(c) Citizenship:
NGN Biomed Opportunity I and NGN GP are Delaware limited
partnerships. NGN Biomed Opportunity I GmbH is a German
limited liability partnership. NGN Capital is a Delaware
limited liability company.
(d) Title of Class of Securities:
Common Stock, par value $0.001 per share ("Common Stock").
(e) CUSIP Number:
Common Stock: 04301Q100
ITEM 3. If this statement is filed pursuant to ss.ss.240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) [_] Broker or dealer registered under section 15 of the Act (15
U.S.C. 78o).
(b) [_] Bank as defined in section 3(a)(6) of the Act (15 U.S.C.
78c).
(c) [_] Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) [_] Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C 80a-8).
(e) [_] An investment adviser in accordance with ss.240.13d-
1(b)(1)(ii)(E);
(f) [_] An employee benefit plan or endowment fund in accordance
with ss.240.13d-1(b)(1)(ii)(F);
(g) [_] A parent holding company or control person in accordance
with ss.240.13d-1(b)(1)(ii)(G);
(h) [_] A savings associations as defined in Section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813);
(i) [_] A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company
Act of 1940 (15 U.S.C. 80a-3);
(j) [_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J).
ITEM 4. Ownership.
As of the date of this Statement, NGN Biomed Opportunity I is the
record holder of 625,920 shares (including 81,938 shares subject to
exercise of warrants) of Common Stock (the "NGN Biomed Opportunity
I Shares"), NGN Biomed Opportunity I GmbH is the record holder of
452,508 shares (including 59,237 shares subject to exercise of
warrants) of Common Stock (the "NGN Biomed Opportunity I GmbH
Shares") and NGN Capital is the record holder of 38,046 shares
subject to exercise of stock options. As sole general partner of
NGN Biomed Opportunity I, NGN GP along with NGN Capital, the sole
general partner of NGN GP, may be deemed to beneficially own the
NGN Biomed Opportunity I Shares. As the sole managing limited
partner of NGN
Page 6 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 7 OF 9 PAGES
--------------------------------------------------------------------------------
Biomed Opportunity I GmbH, NGN Capital may be deemed to
beneficially own the NGN Biomed Opportunity I GmbH Shares. By
virtue of the relationship among NGN Biomed Opportunity I, NGN
Biomed Opportunity I GmbH, NGN GP and NGN Capital, each of the
Reporting Persons may be deemed to share the power to direct the
disposition and vote of the NGN Biomed Opportunity I Shares and the
NGN Biomed Opportunity I GmbH Shares, for an aggregate of 1,116,474
shares of Common Stock (the "Record Shares"). Each Reporting Person
also expressly disclaims beneficial ownership of any shares of
Common Stock of the Issuer, except for the shares, if any, such
Reporting Person holds of record.
The Record Shares represent approximately 6.69% of the Common Stock
outstanding, based upon 16,514,163 shares of Common Stock reported
by the Issuer to be outstanding as of September 30, 2007 in a
Quarterly Report on Form 10-Q filed on November 14, 2007. Shares of
Common Stock that may be acquired pursuant to options and warrants
are deemed outstanding for computing the percentage ownership
beneficially owned.
A. AMOUNT BENEFICIALLY OWNED: 1,116,474
B. PERCENT OF CLASS: 6.69%
C. NUMBER OF SHARES AS TO WHICH EACH PERSON HAS:
I. SOLE POWER TO VOTE OR TO DIRECT THE VOTE: 0
II. SHARED POWER TO VOTE OR TO DIRECT THE VOTE: 1,116,474
III. SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF: 0
IV. SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF:
1,116,474
ITEM 5. Ownership of Five Percent or Less of a Class.
Not applicable.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities, check
the following [_].
Not applicable.
ITEM 6. Ownership of More than Five Percent on Behalf of Another Person.
Not applicable.
ITEM 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on By the Parent Holding Company.
Not applicable.
ITEM 8. Identification and Classification of Members of the Group.
Not applicable.
ITEM 9. Notice of Dissolution of Group.
Not applicable.
ITEM 10. Certifications.
Not applicable.
Page 7 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 8 OF 9 PAGES
--------------------------------------------------------------------------------
SIGNATURE
After reasonable inquiry and to the best of its knowledge and belief, each of
the undersigned certifies that the information set forth in this Statement is
true, complete and correct. We also hereby agree to file this statement jointly
pursuant to the Agreement listed on Exhibit 1 hereto.
Date: December 26, 2007
NGN BIOMED OPPORTUNITY I, L.P.
By: NGN Biomed I GP, L.P., its General Partner
By: NGN Capital LLC, its General Partner
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing Member
NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG
By: NGN Capital, LLC, its Managing Limited Partner
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing General Partner
NGN BIOMED I GP, L.P.
By: NGN Capital LLC, its General Partner
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing Member
NGN CAPITAL LLC
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing Member
Page 8 of 9
--------------------------------------------------------------------------------
CUSIP NO. 04301Q100 13G PAGE 9 OF 9 PAGES
--------------------------------------------------------------------------------
Exhibit 1
---------
AGREEMENT OF JOINT FILING
-------------------------
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the
undersigned hereby agree that only one statement containing the information
required by Schedule 13G need be filed with respect to the ownership by each of
the undersigned of shares of Common Stock of Artes Medical, Inc.
EXECUTED this 26th day of December, 2007.
NGN BIOMED OPPORTUNITY I, L.P.
By: NGN Biomed I GP, L.P., its General Partner
By: NGN Capital LLC, its General Partner
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing Member
NGN BIOMED OPPORTUNITY I GMBH & CO. BETEILIGUNGS KG
By: NGN Capital, LLC, its Managing Limited Partner
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing General Partner
NGN BIOMED I GP, L.P.
By: NGN Capital LLC, its General Partner
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing Member
NGN CAPITAL LLC
By: /s/ John R. Costantino
----------------------------------
John R. Costantino
Managing Member
Page 9 of 9